Corbevax gets emergency use nod for 12-18 age group
- Hyderabad-based Biological E’s Covid-19 vaccine Corbevax was given emergency use nod for the 12-18 age group by the Drugs Controller General of India (DCGI)
- Currently Bharat Biotech’s Covaxin is only administered in India for this age group
Corbevax
- It is India’s first indigenously developed Receptor Binding Domain (RBD) protein subunit vaccine against Covid-19.
- It received emergency use authorization for the adult population in December last year.
- It is built on the traditional subunit vaccine platform.
- Instead of using the whole virus, the platform triggers an immune response by using its fragments, like the spike protein.
- The sub-unit vaccine contains harmless S-protein.
- Once the human immune system recognises the S-protein, it produces antibodies as white blood cells that fight the infection.
Covaxin
- It has been developed by the company Bharat Biotech India (BBIL) in collaboration with ICMR’s National Institute of Virology (NIV).
- It is an “inactivated” vaccine
- It is made by using particles of the Covid-19 virus that were killed, making them unable to infect or replicate.
- Injecting particular doses of these particles serves to build immunity by helping the body create antibodies against the dead virus
Other vaccines approved by DCGI in India
-
Covishield:
-
It is a Recombinant Chimpanzee Adenovirus vector vaccine (Covishield), encoding the SARS-CoV-2 Spike (S) glycoprotein
-
It is a ""non-replicating viral vector""
-
It makes use of another weakened and genetically modified virus, it is based on viral vector based technology
-
It carries the code to make the spike protein that is the spike on the surface of the virus.
-
It is supposed that the immune system of the body will recognise this protein as a threat and work on building antibodies against it.
-
It is being developed by AstraZeneca and the University of Oxford.
-
It is developed and manufactured by the Serum Institute of India(SII) through a licence from AstraZeneca and Oxford.
-
Sputnik V: it is created using different Human Adenoviruses
-
It is a two-dose vaccine.
-
Its efficacy is 91%
-
Sputnik V vaccine is manufactured using vector based platform
-
It is developed by Gamleya Research Institute of Epidemiology and Microbiology in Moscow.
-
It is distributed in India by Dr Reddy’s laboratory.
-
ZyCov – D: it is the second indigenous vaccine next to COVAXIN
-
It is developed on plasmid DNA i.e a piece of DNA of the weakened or killed virus is being used
-
When this DNA piece is injected into the body, the human immune systems learn to respond against the virus.
-
The plasmid is produced using E Coli cells.
-
Its unique feature is that it is needle less vaccine
-
Its efficacy is 66.6%
-
It is developed by the Indian Pharmaceutical company Cadila Healthcare